Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain Metastases

This randomized phase II study aims to investigate whether the addition of bevacizumab to standard corticosteroid therapy results in greater improvement in symptoms and less treatment-induced symptoms compared with standard corticosteroid therapy for patients with symptomatic brain radionecrosis following radiosurgery. It is hypothesized that the addition of bevacizumab to standard care corticosteroids will reduce treatment-induced toxicities and improve neurologic impairments in patients with brain radionecrosis following radiosurgery for brain metastases.

Research Base: Alliance for Clinical Trials in Oncology
NCT ID: NCT02490878
NCI Protocol Number: A221208
Status: Active, not recruiting

For more information see



Radionecrosis, Brain Metastases

Trial Type

Supportive Care/Symptom Management/PROs

See a list of participating sites on